CMS releases Medicaid work requirements guidance for states
Rebecca Pifer Parduhn / healthcaredive - The highly anticipated interim final rule weighs in on key issues for states hustling to operationalize work requirements before the 2027 deadline. But there’s still some gray area — and lots of critics.
AI Summary: The Centers for Medicare & Medicaid Services released a national framework for implementing Medicaid work requirements, giving states guidance on eligibility, reporting and enforcement. The directive outlines guardrails and operational expectations while leaving significant discretion to states, prompting debate over access, administrative burden and potential gaps in coverage during rollout.
Massachusetts sues UnitedHealthcare over alleged $100M in fraudulent Medicaid payments
Elizabeth Casolo / beckershospitalreview - Massachusetts filed a lawsuit against UnitedHealthcare, accusing the insurer of retaining more than $100 million in fraudulent Medicaid payments. The May 29 complaint, filed in a state court, focuses on UnitedHealthcare’s role as a contractor for “Senior …
AI Summary: The Massachusetts attorney general filed a civil suit accusing UnitedHealthcare of submitting improper Medicaid payments, alleging roughly $100 million in fraudulent claims tied to managed‑care contracts. The action seeks recovery and oversight remedies as state regulators press insurers on billing practices, underscoring growing scrutiny of Medicaid managed‑care arrangements.
Florida hospitals lose $2B opioid lawsuit against pharmacies
Ella Jeffries / beckershospitalreview - A Florida judge has ruled in favor of CVS, Walgreens and Walmart in a lawsuit brought by 16 hospitals seeking $2 billion in damages related to the opioid epidemic. Broward County Chief Judge Carol-Lisa Phillips entered judgment for the defendants May 26, …
AI Summary: A Florida court ruling overturned a multibillion‑dollar claim by hospitals against major pharmacy chains, finding in favor of CVS, Walgreens and Walmart in litigation tied to the opioid epidemic. The decision removes a major anticipated payout and reshapes liability questions in the national effort to hold corporate actors accountable for addiction harms — legal teams are predictably thrilled.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.